When Pfizer announced its intention earlier this month to acquire Pharmacia in a stock-for-stock deal valued at $60 billion, it became clear that the trend towards consolidation in big pharma is showing no signs of abating.
When Pfizer announced its intention earlier this month to acquire Pharmacia in a stock-for-stock deal valued at $60 billion, it became clear that the trend towards consolidation in big pharma is showing no signs of abating.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.